14-Aug-2026
AxoGen Earnings Call Highlights Strong Growth, Margin Strain
TipRanks (Tue, 11-Aug 8:21 PM ET)
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
Globe Newswire (Tue, 11-Aug 3:35 PM ET)
PRNewswire (Wed, 29-Jul 7:10 AM ET)
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 29-Jul 7:05 AM ET)
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
Globe Newswire (Mon, 20-Jul 4:05 PM ET)
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Globe Newswire (Wed, 15-Jul 7:00 AM ET)
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
Globe Newswire (Fri, 22-May 11:30 AM ET)
Market Chameleon (Tue, 28-Apr 7:08 AM ET)
Market Chameleon (Tue, 28-Apr 3:33 AM ET)
Axogen Upsizes Public Offering to $124 Million—Early Debt Repayment and Growth in Focus
Market Chameleon (Thu, 22-Jan 3:19 AM ET)
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Axogen trades on the NASDAQ stock market under the symbol AXGN.
As of August 14, 2026, AXGN stock price climbed to $48.73 with 598,563 million shares trading.
AXGN has a beta of 1.52, meaning it tends to be more sensitive to market movements. AXGN has a correlation of 0.12 to the broad based SPY ETF.
AXGN has a market cap of $2.62 billion. This is considered a Mid Cap stock.
Last quarter Axogen reported $70 million in Revenue and $.12 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.03.
In the last 3 years, AXGN traded as high as $49.93 and as low as $3.45.
The top ETF exchange traded funds that AXGN belongs to (by Net Assets): VTI, IWM, VXF, IWO, FESM.
AXGN has outperformed the market in the last year with a price return of +230.1% while the SPY ETF gained +21.6%. AXGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.9% and +17.8%, respectively, while the SPY returned +4.8% and +4.7%, respectively.
AXGN support price is $46.64 and resistance is $49.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXGN shares will trade within this expected range on the day.